Goldman Sachs’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Goldman Sachs’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4,900	Closed	-$1.06M	–	5963
2023 Q2	$1.06M	Buy	+4,900	New	+$1.05M	﹤0.01%	4304
2022 Q1	–	Sell	-15,000	Closed	-$1.97M	–	7001
2021 Q4	$1.97M	Hold	15,000	–	–	﹤0.01%	4268
2021 Q3	$1.83M	Buy	15,000 +4,700	+46%	+$543K	﹤0.01%	4277
2021 Q2	$1.17M	Hold	10,300	–	–	﹤0.01%	4638
2021 Q1	$1.24M	Buy	+10,300	New	+$1.17M	﹤0.01%	4446

Other funds holding KRTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Goldman Sachs's KRTX Position: Q1 2024 in Review

Goldman Sachs sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 201,270 shares — an estimated $63.7M sold.

Goldman Sachs first reported a position in KRTX in Q2 2019 and held it in 18 quarters. The position peaked at $63.7M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

Goldman Sachs reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Goldman Sachs sold 201,270 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $63.7M.
Goldman Sachs first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and held it in 18 quarters.
Goldman Sachs's Karuna Therapeutics, Inc. Common Stock position peaked at $63.7M in Q4 2023.
2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Goldman Sachs's 13F filing for Q1 2024, filed 15 May 2024.